Get started
Author

Vanessa Nicole Sarli

Observed names: V. N. Sarli, V.N. Sarli, Vanessa N Sarli, Vanessa N. Sarli, Vanessa Sarli
OpenAlex ID: A5081006682
Pilot Study of Circulating Tumor Cells in Early-Stage and Metastatic Uveal Melanoma
2019 · Kartik Anand, Jason Roszik, et al. · Cancers · 44
PDF
Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers
2022 · Sridevi Addanki, Salyna Meas, et al. · International Journal of Molecular Sciences · 43
PDF
Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA
2024 · Jennifer H. Chen, Sridevi Addanki, et al. · BMC Cancer · 32
PDF
Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine
2021 · Balraj Singh, Vanessa N. Sarli, et al. · Oncotarget · 16
PDF
Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching ‘liquid biopsy’ and quantitative tumor modeling
2018 · Sweet Ping Ng, Houda Bahig, et al. · BMC Cancer · 16
PDF
Safety and early biologic effects of phase 1 PERIO-01 trial of pressure-enabled drug delivery (PEDD) of TLR9 agonist SD-101 and immune checkpoint inhibition (ICI) in uveal melanoma metastatic to the liver (MUM).
2023 · Kamaneh Montazeri, Diwakar Davar, et al. · Journal of Clinical Oncology · 11
A usable model of “decathlon winner” cancer cells in triple-negative breast cancer: survival of resistant cancer cells in quiescence
2018 · Balraj Singh, Vanessa N. Sarli, et al. · Oncotarget · 11
PDF
Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential
2019 · Balraj Singh, Vanessa N. Sarli, et al. · Oncotarget · 10
PDF
Presence of Circulating Tumor Cells Predates Imaging Detection of Relapse in Patients with Stage III Melanoma
2023 · Anthony Lucci, Sridevi Addanki, et al. · Cancers · 9
PDF
Sensitization of Resistant Cells with a BET Bromodomain Inhibitor in a Cell Culture Model of Deep Intrinsic Resistance in Breast Cancer
2023 · Balraj Singh, Vanessa N. Sarli, et al. · Cancers · 7
PDF
Sensitization of Resistant Breast Cancer Cells with a Jumonji Family Histone Demethylase Inhibitor
2022 · Balraj Singh, Vanessa N. Sarli, et al. · Cancers · 6
PDF
1534 Clinical activity of SD-101 with immune checkpoint inhibition (ICI) in metastatic uveal melanoma liver metastasis (MUM-LM) from the PERIO-01 Phase 1 trial
2023 · Sapna P Patel, Richard Carvajal, et al. · 4
PDF
Is there a role for liquid biopsy in the surveillance of parathyroid carcinoma?
2023 · Thomas Szabo Yamashita, Aditya S. Shirali, et al. · Surgery · 3
Abstract 5881: PERIO-01: Initial safety experience and immunologic effects of a Class C TLR9 agonist using pressure- enabled drug delivery in a phase 1 trial of hepatic arterial infusion of SD-101 +/- checkpoint inhibition in metastatic uveal melanoma
2023 · Sapna P. Patel, Cara Haymaker, et al. · Cancer Research · 2
Role of Liquid Biopsy in Clinical Decision-Making for Breast Cancer
2019 · Carolyn Hall, Vanessa Sarli, et al. · Current Breast Cancer Reports · 2
Abstract P1-01-28: Molecular Residual Disease Precedes Radiographic Confirmation of Recurrence in Patients with Stage III Inflammatory Breast Cancer
2025 · Jennifer Chen, Salyna Meas, et al. · Clinical Cancer Research · 1
16P Monitoring response to neoadjuvant chemotherapy in TNBC using circulating tumor DNA
2023 · A. Lucci, S. Addanki, et al. · ESMO Open · 1
PDF
Circulating tumour cell and cell-free DNA kinetics during radiotherapy in patients with intact head and neck squamous cell carcinoma
2020 · Sweet Ping Ng, Carolyn S Hall, et al. · medRxiv · 1
PDF
Abstract A12: Presence of circulating tumor cells is an adverse risk factor for early-stage uveal melanoma
2020 · Jason Roszik, Dan Gombos, et al. · Cancer Research · 1
Characterization of CTC-HER2 Status in Patients with HER2-Low Invasive Breast Cancer
2026 · Jennifer H. Chen, Salyna Meas, et al. · Cancers
Response to neoadjuvant chemotherapy in both the breast and lymph nodes in patients with inflammatory breast cancer.
2026 · Megan McClanahan, Vanessa Nicole Sarli, et al. · Journal of Clinical Oncology
Abstract 7438: Residual disease on a dish: A practical approach to deep intrinsic resistance in melanoma
2026 · Balraj Singh, Vanessa N. Sarli, et al. · Cancer Research
A phenotype-based cell culture model of melanoma cells that persist as residual disease after therapies leading to recurrence
2026 · Balraj Singh, Vanessa Sarli, et al. · Research Square
PDF
Abstract PS2-01-25: Does surgery in a specialized clinic improve locoregional recurrence rates in Inflammatory Breast Cancer?
2026 · V. N. Sarli, S. Meas, et al. · Clinical Cancer Research
Abstract A010: A cell culture model of quiescent melanoma cell state that governs cancer evolution, therapy resistance, and recurrence/metastasis
2025 · Balraj Singh, Vanessa N. Sarli, et al. · Cancer Research
Works count: 44
Citation count: 219
H-index: 9
I10-index: 8
Year
Topic
Type